A correction to prior research clarifies the role of telomerase in myeloid cell function and atherosclerosis progression. The findings demonstrate that telomerase loss in immune cells accelerates dyslipidemia, foam cell accumulation, and downstream organ damage—connecting immune cell aging to systemic cardiovascular and pulmonary pathology.
Key Points
- Telomerase deletion in myeloid cells promotes foam cell differentiation
- Immune cell aging accelerates dyslipidemia and atherosclerotic progression
- Telomerase loss in immune cells triggers cardiac and pulmonary dysfunction
Longevity Analysis
Telomerase activity in immune cells functions as a checkpoint for healthy aging. When myeloid cells lose telomerase capacity, they lose the ability to maintain replicative potential during the chronic inflammatory state that drives atherosclerosis. This creates a cascade: shortened immune cell lifespan → impaired lipid handling → foam cell accumulation → vascular and organ damage. This research underscores that aging isn't uniform across tissues; the immune system's capacity to regenerate and respond appropriately is foundational to preventing the metabolic dysregulation and inflammatory burden that characterize cardiovascular aging. Interventions targeting immune cell telomerase preservation or function may represent a deeper point of leverage than lipid management alone.
Original published by Wiley Aging Cell.